Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast02: Dato-DXd vs investigator’s choice chemotherapy in first-line unresectable locally recurrent or metastatic triple-negative breast cancer not eligible for PD-1/PD-L1 inhibitors
CTR20221621Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2022; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221621.